Long QT Syndrome Management during and after Pregnancy

Authors, Journal, Affiliations, Type, DOI

• Agne Marcinkeviciene, Diana Rinkuniene, Aras Puodziukynas
• Department of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania
• Medicina 2022;58(11):1694
• Review article
• DOI: https://doi.org/10.3390/medicina58111694

Overview

LQTS complicates pregnancy through a paradoxical risk pattern: pregnancy itself is relatively protective (increased heart rate shortens the QT interval), but the 9-month postpartum period carries a 2.7-fold increased cardiac event risk and a 4.1-fold increased risk of life-threatening events compared to the prepregnancy period. LQT2 patients are disproportionately affected postpartum, attributed to the sharp drop in progesterone — a hormone with antiarrhythmic properties. Beta-blockers (particularly propranolol and nadolol, both superior to metoprolol) are Class I throughout pregnancy and the postnatal period, reducing major cardiac event rates from 3.7% to 0.8% in the high-risk postpartum window.

Keywords

Long QT syndrome; pregnancy; β-blocker

Key Takeaways

Epidemiology and Background

• LQTS prevalence approximately 1:2000; ~90% inherited (autosomal dominant), ~10% de novo. Three major subtypes — LQT1 (KCNQ1), LQT2 (KCNH2), LQT3 (SCN5A) — account for ~80% of all LQTS cases.
• Women with LQTS have longer QTc and higher risk of polymorphic VA and SCD than men, attributed to sex hormone differences affecting IKr.
• Subtype-specific triggers: LQT1 — exercise/swimming; LQT2 — auditory stimuli/emotion; LQT3 — rest/sleep.

Physiological Changes in Pregnancy

• Increased heart rate during pregnancy shortens QT intervals — relatively protective in LQTS.
• Postpartum: rapid hemodynamic changes, decreased heart rate, QT prolongation; altered sleep patterns, physiological stress, intense auditory stimuli contribute to adrenergically mediated events.
• Seth et al. (2007): the first 40 weeks postpartum carry elevated risk of syncope, aborted CA, and SCD vs. prepregnancy 40 weeks. 9-month postpartum period: 2.7-fold elevated cardiac emergency risk; 4.1-fold elevated life-threatening event risk.
• After 9 months postpartum, risk reverts to baseline prepregnancy level.
• LQT2 postpartum risk is highest compared to LQT1 and LQT3.

Sex Hormones and Arrhythmogenesis

• Estradiol: inhibits IKr, steepens QT/RR ratio, prolongs cardiac refractoriness, promotes polymorphic VA and SCD — proarrhythmic.
• Progesterone: reduces bigeminy, couplets, and polymorphic VT occurrence; protective against SCD in LQT2 rabbit models (Odening et al.).
• High progesterone during pregnancy is protective; its postpartum fall is mechanistically linked to postpartum arrhythmias in LQT2 patients.
• Case report (Odening 2016): QTc normalised during pregnancy/breastfeeding but re-prolonged when breastfeeding ceased and hormone-based contraceptives were stopped — direct hormonal influence on QTc.
• No systematic reviews exist evaluating sex hormone effects on QT in women with congenital LQTS.

Management — Beta-Blockers

• Beta-blockers are the cornerstone of LQTS management in pregnancy; Class I per AHA/ACC/HRS 2017 and ESC 2018 cardiovascular disease in pregnancy guidelines.
• Ishibashi et al. (multicentre, 136 pregnancies, 76 women): 14 (11%) cardiac events in non-beta-blocker group; zero events in beta-blocker group.
• Event rate reduction: 3.7% → 0.8% with beta-blocker use in the postpartum period.
• Non-selective beta-blockers (propranolol, nadolol) are superior to metoprolol in preventing cardiac events in symptomatic LQTS. Propranolol has superior QTc-shortening vs. nadolol and metoprolol, especially in high-risk patients.
• Beta-blockers are associated with lower birthweight (significant difference; p=0.024), but birth weight was within normal range; catch-up growth occurs in first year of life. No significant differences in congenital malformations.
• Meta-analysis (Yakoob 2013): first-trimester beta-blockers — no increased odds of major non-organ-specific birth defects; 2-fold increase in cardiovascular defects and >3-fold in oral clefts and neural tube defects observed, but data are heterogeneous and limited.
• Beta-blockers secreted in breast milk but risk of adverse effects is low with normal neonatal renal and hepatic function.
• Recommended for at least 40 weeks after delivery.

Management — Antiarrhythmic Drugs

• Amiodarone (pregnancy risk category D): contraindicated — prolongs QT, associated with fetal growth retardation, premature labour, and fetal hypothyroidism.
• Mexiletine (class IB Na⁺ channel blocker): add-on therapy in LQT3; shortens QT interval significantly.
• Ranolazine (pregnancy risk category C): add-on option in LQT3; reduces QT in LQT3-SCN5A-D1790G mutation (Chorin et al.); variable genotype response in LQT3 requires individual biophysical assessment.
• Antiemetics (used in hyperemesis gravidarum) may prolong the QT interval — monitor carefully.

Device Therapy

• ICD implantation should be considered before pregnancy in women with high SCD risk factors.
• ICD during pregnancy is safe under appropriate management; does not increase lead prolapse, lead dysfunction, or lead thrombus risk.
• Preferred: single-lead ICD; safe after 8 weeks gestation.
• Device programming: increase threshold for shock therapies by prolonging tachycardia detection duration to prevent unnecessary shocks for self-terminating episodes.
• Immediate electrical cardioversion recommended for sustained VT regardless of hemodynamic impact.

Risk Stratification and Delivery

• Risk factors predicting cardiac arrest: LQT2 or LQT3 genotype, prior events, degree of QT prolongation.
• Three-tier risk stratification for labour (ESC 2018; Roston et al. 2020):
  • Low risk: No prior events and QTc ≤470 ms → Level 1 surveillance
  • Medium risk: Remote events, or no prior events with QTc ≥470 ms → Level 2 surveillance at tertiary centre
  • High risk: Recent arrhythmic syncope, seizures, CA, or persistent VA in last 1 year on adequate therapy → Level 3 surveillance; Caesarean delivery recommended
• Induction of labour considered at 40 weeks gestation.
• Vaginal delivery considered safest mode in absence of obstetric contraindications (low/medium risk).
• Anesthesia: combined spinal-epidural preferred (minimises sympathetic activation); spinal anesthesia alone avoided (sudden hemodynamic changes → VA risk); epidural allows gradual hemodynamic alteration.
• Continuous ECG telemetry during labour for moderate/high risk; IV beta-blocker availability; IV antiarrhythmics (lidocaine, mexiletine) for emergencies; esmolol for acute rate control.

Postpartum Follow-Up

• No standardised general recommendations exist for postpartum follow-up in LQTS.
• Suggested: cardiologist review within first weeks postpartum, then monthly for first 9 months; ECG evaluation; dose adjustment of beta-blockers as needed.

Limitations of the Document

• Review article; all cited evidence is low-to-moderate quality (retrospective studies, case reports, expert consensus); no randomised clinical trials in LQTS pregnancy management.
• No comparative trial data on different beta-blocker efficacy in pregnant LQTS patients.
• Lack of systematic data on sex hormone effects on QT in women with congenital LQTS (vs. drug-induced LQTS and animal models).
• Small heterogeneous studies underlie birth defect risk estimates; difficult to interpret.
• Postpartum follow-up interval recommendations are facility-dependent, not guideline-standardised.

Key Concepts Mentioned

• concepts/Torsades-de-Pointes — central arrhythmia of LQTS; sex hormone modulation of risk postpartum
• concepts/LQTS-Pregnancy-Management — the primary new concept created from this source
• concepts/Left-Cardiac-Sympathetic-Denervation — mentioned as post-partum option (best delayed until postpartum)

Key Entities Mentioned

• entities/Long-QT-Syndrome — primary clinical entity; management across all subtypes
• entities/KCNQ1 — LQT1 subtype
• entities/KCNH2 — LQT2 subtype; highest postpartum risk
• entities/SCN5A — LQT3 subtype; mexiletine/ranolazine add-on therapy

Wiki Pages Updated

• wiki/sources/lqts-pregnancy-medicina-2022.md — created
• wiki/concepts/LQTS-Pregnancy-Management.md — created
• wiki/entities/Long-QT-Syndrome.md — pregnancy/postpartum section added
• wiki/concepts/Torsades-de-Pointes.md — sex hormone and postpartum risk updated
• wiki/sourceindex.md — entry added
• wiki/wikiindex.md — entry added